January 4, 2022 -
DALLAS, TEXAS and TORONTO, ONTARIO – (Jan. 4, 2022) MolecuLight Inc., the leader in point-of-care fluorescence imaging for real-time detection of wounds containing elevated bacterial loads, announces that SWK Holdings Corporation has provided $10M USD structured debt to support MolecuLight’s global commercial expansion. SWK Holdings Corporation (Nasdaq: SWKH) is
… Read MoreOctober 28, 2021 -7 Clinical Posters and Presentations Highlight the Breadth of Clinical Benefits of the MolecuLight Device for Wound Care Applications
Toronto, ONTARIO and Las Vegas, NEVADA– (October 28, 2021) MolecuLight Inc., the leader in point-of-care fluorescence imaging for real-time detection of wounds containing elevated bacterial loads, announces the presentation of
… Read MoreOctober 19, 2021 -
Charlotte, NC, and Pittsburgh, PA, October 19, 2021 – Joerns Healthcare, a healthcare technology and equipment services company, announces the addition of the MolecuLight i:X® and DX™ wound imaging platforms to its wound management portfolio through an agreement with MolecuLight Corp. to provide MolecuLight’s fluorescence imaging technology
… Read MoreOctober 14, 2021 -MolecuLight Platform is Becoming the Standard-of-Care for Real-Time Imaging of Elevated Bacterial Burden in Wounds Across All Wound Care Settings
TORONTO, CANADA – (October 14, 2021) MolecuLight Inc., the leader in point-of-care fluorescence imaging for real-time detection of wounds containing elevated bacterial loads, announced the launch of the MolecuLightDX™,
… Read MoreOctober 12, 2021 -Published results describe use of point-of-care imaging for the early detection and proactive management of wound-related cellulitis
TORONTO, CANADA – (October 12, 2021) MolecuLight Inc., the leader in point-of-care fluorescence imaging for real-time detection of wounds containing elevated bacterial loads, announced the publication in International Wound
… Read MoreSeptember 23, 2021 -New FDA Clearance Illustrates the Utility of the i:X to Reliably Predict Pseudomonas Aeruginosa, a Bacterial Pathogen that Precludes Wound Healing and Often Evades Conventional Treatment Methods
TORONTO, CANADA – (September 23, 2021) MolecuLight Inc., the leader in point-of-care fluorescence imaging for real-time detection of wounds containing elevated bacterial
… Read MoreJuly 7, 2021 -Published results provides guidelines to standardize use of fluorescence imaging among wound care providers to enhance the quality of patient care
TORONTO, CANADA – (July 7 2021) MolecuLight Inc., the leader in point-of-care fluorescence imaging for real-time detection of wounds containing elevated bacterial loads, announced the publication of an
… Read MoreJune 22, 2021 -LMT’s Comprehensive Sales and Support Network to Meet Significant Demand for the MolecuLight i:X® in the Wound Care Community
TORONTO, CANADA and QUEENSLAND, AUSTRALIA– (June 22, 2021) MolecuLight Inc., the leader in point-of-care fluorescence imaging for detection of wounds containing elevated bacterial loads, announces it has signed… Read More
May 18, 2021 -Results of Clinical Integration Project of MolecuLight i:X® Point-of-Care Imaging Device Illustrate Improved Access, Effectiveness and Efficiency of Wound Care
TORONTO, Ontario – (May 18, 2021) MolecuLight Inc., the leader in point-of-care fluorescence imaging for detection of wounds containing elevated bacterial loads, is helping to improve wound care in
… Read More
MolecuLight is SOC ll®
Type l Accredited:
MolecuLight awarded
Premier’s Technology
Breakthrough Designation
MolecuLight i:X
is designated as a:
MolecuLight included
in ISWCAP Consensus
Guidelines:
MolecuLight is a proud
corporate member of:
©2024
The MolecuLight® i:X and MolecuLightDX™ Imaging Devices are approved by Health Canada for sale in Canada and has CE marking for sale in the European Union.
The MolecuLight™ i:X and DX Imaging Devices have received FDA clearance.